Target intelligence / Profile preview

Polyunsaturated fatty acids in cell membranes (PUFAs)

Target
PUFAs
Molecular classification
Lipid, Phospholipid component, Structural molecule
01

Overview

Polyunsaturated fatty acids (PUFAs) are essential structural components of the eukaryotic lipid bilayer, primarily incorporated into phospholipids such as phosphatidylethanolamine and phosphatidylcholine (Alberts et al., 2014). These molecules, characterized by having two or more double bonds in their carbon chain, are critical for maintaining membrane fluidity, permeability, and the proper orientation of transmembrane proteins. PUFAs also serve as the primary precursors for signaling molecules like prostaglandins, leukotrienes, and thromboxanes, which mediate inflammatory and immune responses (Dixon et al., 2012). In pathology, membrane PUFAs are the specific substrates for lipid peroxidation; when oxidized by reactive oxygen species or lipoxygenases, they trigger ferroptosis, a form of regulated iron-dependent cell death (Yang et al., 2016). Therapeutic strategies targeting membrane PUFAs include the use of deuterated fatty acids (e.g., RT-001) to stabilize the membrane against oxidative damage in neurodegenerative diseases or the administration of specific PUFAs to sensitize cancer cells to ferroptosis-inducing agents (Shchepinov, 2007; Conrad et al., 2018).

Other names
Membrane polyunsaturated fatty acidsPUFA-containing phospholipidsMembrane PUFAsPolyunsaturated lipids
02

Mechanism of action

Stabilization of the lipid bilayer against non-enzymatic lipid peroxidation via kinetic isotope effects or modulation of membrane composition to alter sensitivity to ferroptotic cell death.

03

Biological functions

Membrane fluidity regulationSignal transductionCell death (Ferroptosis)Precursor for bioactive lipid mediators (e.g., eicosanoids)Regulation of membrane protein activity
04

Disease associations

Neurodegenerative disease (e.g., Friedreich's ataxia, ALS)CancerInflammationCardiovascular diseaseIschemia-reperfusion injury
05

Safety considerations

Disruption of normal eicosanoid signaling pathwaysPotential for systemic pro-inflammatory or anti-inflammatory imbalanceAlteration of membrane-bound enzyme kineticsBioaccumulation and metabolic integration of synthetic analogs
06

Interacting drugs

RT-001 (Deuterated ethyl linoleate)

5 more in the full profile.

07

Biomarkers

Malondialdehyde (MDA)4-hydroxynonenal (4-HNE)F2-isoprostanesC11-BODIPY (581/591) oxidation ratioGPX4 activity levels

Beyond the preview

Go deeper on Polyunsaturated fatty acids in cell membranes (PUFAs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyunsaturated fatty acids in cell membranes (PUFAs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call